Further extended studies are, however, needed to evaluate whether the analysis of individual and combined variations in the HLA-E-restricted immune response may serve as prognostic markers for malignant EBV-associated diseases and to assess whether drug-induced blocking of NKG2A may provide a therapeutic option for EBV+ lymphomas. This evidence concerns the gene KLRC1 and lymphoma.